Table 1.

Characteristics of cases and controls.

Cases	Type of Cancer	Sex	Age at enrolment (years)	Age at treatment (years)	Cumulative Anthracycline Dose (mg/m2)	Post treatment Left Ventricular Ejection Fraction (LVEF)	RARG genotype
DIC-001	Breast	F	70	56	300 (DOX)	20%	WT/WT
DIC-002	Sarcoma	F	52	47	450 (DOX)	36%	WT/WT
DIC-003*	Breast	F	87	68	320 (DOX)	36%	WT/S427L
DIC-008	Breast	F	67	48	300 (DOX)	20%	WT/WT
Controls
DIC-014**	Sarcoma	F	32	15	420 (DOX)	60%	WT/WT
DIC-021	Lymphoma	F	27	11	180 (DAUN)	60%	WT/S427L
DIC-023*	Breast	F	65	51	320 (DOX)	55%	WT/WT

*Used for genome editing experiments.

**Used for knock out experiments.

DOX: doxorubicin, DAUN: daunorubicin (DOX:DAUN 1:1 equivalence ratio used by clinical groups for assessment of cardiotoxicity^13–17).